Ascletis Pharma boosts share buyback to HK$500m

Ascletis Pharma Inc. announced an increase in its share repurchase fund to up to HK$500 million, up from the previously announced HK$300 million. This decision, resolved on December 15, 2025, reflects the board's belief that the company's stock is undervalued and aims to enhance shareholder returns. The repurchases will be funded by internal financial resources and are part of the Repurchase Mandate granted at the AGM on May 22, 2025.

The upsized repurchase follows significant achievements by Ascletis, including positive results for several drug candidates. These include ASC30 for weight loss, ASC47 for obesity treatment, ASC50 for an IL-17 inhibitor, and China NMPA acceptance of a New Drug Application for denifanstat (ASC40) for acne.

As of December 15, 2025, Ascletis has already repurchased 4,586,000 ordinary shares for approximately HK$54.28 million since October 2, 2025. The company emphasizes that the Updated Proposed Share Repurchase underscores its confidence in its long-term business prospects and growth potential. Shareholders and potential investors are advised to exercise caution as repurchases are subject to market conditions and board discretion.